{"id":"mesalamine-granules","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL704","moleculeType":"Small molecule","molecularWeight":"153.14"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Mesalamine is a type of aminosalicylate that is released in the colon, where it reduces inflammation and prevents symptoms of ulcerative colitis. This is achieved by inhibiting the production of pro-inflammatory mediators and reducing the adhesion of leukocytes to the intestinal mucosa.","oneSentence":"Mesalamine works by releasing aminosalicylates in the colon to reduce inflammation and prevent symptoms of ulcerative colitis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:47.060Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mild to moderate ulcerative colitis"},{"name":"Moderate to severe ulcerative colitis"}]},"trialDetails":[{"nctId":"NCT04920149","phase":"PHASE2","title":"Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome","status":"RECRUITING","sponsor":"Ann-Sofie Backman","startDate":"2022-03-21","conditions":"Lynch Syndrome, Colon Cancer, Colon Neoplasm","enrollment":150},{"nctId":"NCT02522780","phase":"PHASE3","title":"Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2016-02-01","conditions":"Ulcerative Colitis","enrollment":276},{"nctId":"NCT02522767","phase":"PHASE3","title":"Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2015-10","conditions":"Ulcerative Colitis","enrollment":228},{"nctId":"NCT03689673","phase":"","title":"Study of the Effectiveness of ETIASA® (Sustained Release 5-Aminosalicylate) in Maintenance Treatment of Ulcerative Colitis (UC)","status":"COMPLETED","sponsor":"Ipsen","startDate":"2013-04-24","conditions":"Ulcerative Colitis","enrollment":607},{"nctId":"NCT00767728","phase":"PHASE3","title":"Mesalamine Pellet to Maintain Remission of Mild to Moderate Ulcerative Colitis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2004-12","conditions":"Ulcerative Colitis","enrollment":256},{"nctId":"NCT00744016","phase":"PHASE3","title":"Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2004-12","conditions":"Ulcerative Colitis","enrollment":305},{"nctId":"NCT01177410","phase":"PHASE2","title":"Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2010-07","conditions":"Irritable Bowel Syndrome With Diarrhea","enrollment":148},{"nctId":"NCT00622375","phase":"PHASE1","title":"PK Study of Encapsulated Mesalamine Granules in Healthy Volunteers","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2008-02","conditions":"Healthy","enrollment":24},{"nctId":"NCT00326209","phase":"PHASE3","title":"Long-Term Safety and Tolerability of Mesalamine Pellets in Participants With Ulcerative Colitis in Remission","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2005-12-22","conditions":"Ulcerative Colitis","enrollment":393},{"nctId":"NCT03716388","phase":"PHASE3","title":"Fecal Microbiota Therapy Vs 5-aminosalicylates for Induction of Remission in Newly Diagnosed Mild-moderately Active UC","status":"UNKNOWN","sponsor":"Dayanand Medical College and Hospital","startDate":"2018-12-01","conditions":"Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate","enrollment":20},{"nctId":"NCT00695643","phase":"PHASE3","title":"Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis","status":"TERMINATED","sponsor":"Dr. Falk Pharma GmbH","startDate":"2008-01","conditions":"Diverticulitis","enrollment":345},{"nctId":"NCT01038739","phase":"PHASE3","title":"Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis","status":"TERMINATED","sponsor":"Dr. Falk Pharma GmbH","startDate":"2010-01","conditions":"Diverticulitis","enrollment":330},{"nctId":"NCT00449722","phase":"PHASE3","title":"OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Dr. Falk Pharma GmbH","startDate":"2005-07","conditions":"Ulcerative Colitis","enrollment":380},{"nctId":"NCT01627262","phase":"PHASE2","title":"Mesalamine for Uncomplicated Diverticular Disease: a Randomized, Double-blind, Placebo-controlled Study","status":"COMPLETED","sponsor":"Dr. Falk Pharma GmbH","startDate":"2002-05","conditions":"Colonic Diverticulosis","enrollment":123},{"nctId":"NCT00737789","phase":"PHASE3","title":"Mesalazine 4g Once Daily Versus 4g in Two Divided Doses in Active Ulcerative Colitis.","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2008-11","conditions":"Ulcerative Colitis","enrollment":206},{"nctId":"NCT01841099","phase":"PHASE1, PHASE2","title":"Mesalamine in Environmental Enteropathy","status":"COMPLETED","sponsor":"Kelsey Jones","startDate":"2013-06","conditions":"Malnutrition","enrollment":44},{"nctId":"NCT00450086","phase":"PHASE3","title":"Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous Colitis","status":"COMPLETED","sponsor":"Dr. Falk Pharma GmbH","startDate":"2007-03","conditions":"Collagenous Colitis","enrollment":92},{"nctId":"NCT01316718","phase":"PHASE4","title":"Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)","status":"COMPLETED","sponsor":"University of Nottingham","startDate":"2011-03","conditions":"Irritable Bowel Syndrome With Diarrhoea","enrollment":108},{"nctId":"NCT00747110","phase":"PHASE3","title":"Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC)","status":"COMPLETED","sponsor":"Dr. Falk Pharma GmbH","startDate":"2007-10","conditions":"Colitis, Ulcerative","enrollment":343},{"nctId":"NCT00746447","phase":"PHASE3","title":"Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)","status":"COMPLETED","sponsor":"Dr. Falk Pharma GmbH","startDate":"2005-05","conditions":"Colitis, Ulcerative, Recurrence","enrollment":648}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Salofalk granules","Mesalazine","Rowasa"],"phase":"phase_3","status":"active","brandName":"mesalamine granules","genericName":"mesalamine granules","companyName":"Dr. Falk Pharma GmbH","companyId":"dr-falk-pharma-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mesalamine works by releasing aminosalicylates in the colon to reduce inflammation and prevent symptoms of ulcerative colitis. Used for Mild to moderate ulcerative colitis, Moderate to severe ulcerative colitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}